Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade

Choy,Cecilia; Raytis,John L.; Smith,David D.; Duenas,Matthew; Neman,Josh; Jandial,Rahul; Lew,Michael W.

doi:10.3892/or.2016.4710

Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade

Authors:
- Cecilia Choy
- John L. Raytis
- David D. Smith
- Matthew Duenas
- Josh Neman
- Rahul Jandial
- Michael W. Lew
View Affiliations

Affiliations: Division of Neurosurgery, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA, Department of Anesthesiology, City of Hope, Duarte, CA 91010, USA, Department of Biostatistics, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA, Department of Neurosurgery, Keck School of Medicine at the University of Southern California, Los Angeles, CA 90089, USA
Published online on: March 28, 2016 https://doi.org/10.3892/or.2016.4710
Pages: 3135-3142
Copyright: © Choy et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In response to recent studies, we investigated an association between perioperative β-blockade and breast cancer metastases. First, a retrospective study examining perioperative β-blocker use and cancer recurrence and metastases was conducted on 1,029 patients who underwent breast cancer surgery at the City of Hope Cancer Center between 2000 and 2010. We followed the clinical study and examined proliferation, migration, and invasion in vitro of primary and brain-metastatic breast cancer cells in response to β2-activation and inhibition. We also investigated in vivo the metastatic potential of propranolol-treated metastatic cells. For stage II breast cancer patients, perioperative β-blockade was associated with decreased cancer recurrence using Cox regression analysis (hazard's ratio =0.51; 95% CI: 0.23-0.97; p=0.041). Triple-negative (TN) brain-metastatic cells were found to have increased β2-adrenergic receptor mRNA and protein expression relative to TN primary cells. In response to β2-adrenergic receptor activation, TN brain-metastatic cells also exhibited increased cell proliferation and migration relative to the control. These effects were abrogated by propranolol. Propranolol decreased β2-adrenergic receptor-activated invasion. In vivo, propranolol treatment of TN brain-metastatic cells decreased establishment of brain metastases. Our results suggest that stress and corresponding β2-activation may promote the establishment of brain metastases of TN breast cancer cells. In addition, our data suggest a benefit to perioperative β-blockade during surgery-induced stress with respect to breast cancer recurrence and metastases.

View Figures

View References

1	Schouten LJ, Rutten J, Huveneers HA and Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 94:2698–2705. 2002. View Article : Google Scholar : PubMed/NCBI
2	Pestalozzi BC: Brain metastases and subtypes of breast cancer. Ann Oncol. 20:803–805. 2009. View Article : Google Scholar : PubMed/NCBI
3	Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, Li H, Lin YC, Chang HK, Chao TC, et al: Distant metastasis in triple-negative breast cancer. Neoplasma. 60:290–294. 2013. View Article : Google Scholar : PubMed/NCBI
4	Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN and Gonzalez-Angulo AM: Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 29:2645–2652. 2011. View Article : Google Scholar : PubMed/NCBI
5	Barron TI, Connolly RM, Sharp L, Bennett K and Visvanathan K: Beta blockers and breast cancer mortality: A population-based study. J Clin Oncol. 29:2635–2644. 2011. View Article : Google Scholar : PubMed/NCBI
6	Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO and Entschladen F: Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 1:628–638. 2010. View Article : Google Scholar
7	Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM, Li H, Hambrecht AC, Roberts E and Jandial R: Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci USA. 111:984–989. 2014. View Article : Google Scholar : PubMed/NCBI
8	Termini J, Neman J and Jandial R: Role of the neural niche in brain metastatic cancer. Cancer Res. 74:4011–4015. 2014. View Article : Google Scholar : PubMed/NCBI
9	Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8:98–101. 1989.PubMed/NCBI
10	Purves D, Augustine GJ, Fitzpatrick D, Katz LC, LaMantia AS, McNamara JO and Williams SM: Neuroscience. 2nd edition. Sinauer Associates; Sunderland, MA: 2001
11	Schuller HM and Cole B: Regulation of cell proliferation by beta-adrenergic receptors in a human lung adenocarcinoma cell line. Carcinogenesis. 10:1753–1755. 1989. View Article : Google Scholar : PubMed/NCBI
12	Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, et al: Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 15:2695–2702. 2009. View Article : Google Scholar : PubMed/NCBI
13	Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, et al: The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 70:7042–7052. 2010. View Article : Google Scholar : PubMed/NCBI
14	Huang XY, Wang HC, Yuan Z, Huang J and Zheng Q: Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via β-adrenergic receptor-dependent activation of P38/MAPK pathway. Hepatogastroenterology. 59:889–893. 2012.
15	Strell C, Niggemann B, Voss MJ, Powe DG, Zanker KS and Entschladen F: Norepinephrine promotes the β1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROα release. Mol Cancer Res. 10:197–207. 2012. View Article : Google Scholar
16	Gottschalk A, Sharma S, Ford J, Durieux ME and Tiouririne M: Review article: The role of the perioperative period in recurrence after cancer surgery. Anesth Analg. 110:1636–1643. 2010. View Article : Google Scholar : PubMed/NCBI
17	Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A and Ben-Eliyahu S: Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 15:2042–2052. 2008. View Article : Google Scholar : PubMed/NCBI
18	Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S and Cole SW: Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 12:369–375. 2006. View Article : Google Scholar : PubMed/NCBI
19	Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D and Zhang M: Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep. 22:825–830. 2009.PubMed/NCBI
20	Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, Mantovani A and Allavena P: Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 64:8420–8427. 2004. View Article : Google Scholar : PubMed/NCBI
21	Entschladen F, Drell TL IV, Lang K, Joseph J and Zaenker KS: Tumour-cell migration, invasion, and metastasis: Navigation by neurotransmitters. Lancet Oncol. 5:254–258. 2004. View Article : Google Scholar : PubMed/NCBI
22	Tang J, Li Z, Lu L and Cho CH: β-adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 23:533–542. 2013. View Article : Google Scholar : PubMed/NCBI
23	Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, et al: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 12:939–944. 2006. View Article : Google Scholar : PubMed/NCBI
24	Gille E, Lemoine H, Ehle B and Kaumann AJ: The affinity of (-)-propranolol for beta 1- and beta 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch Pharmacol. 331:60–70. 1985. View Article : Google Scholar : PubMed/NCBI
25	Masur K, Niggemann B, Zanker KS and Entschladen F: Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res. 61:2866–2869. 2001.PubMed/NCBI
26	Drell TL IV, Joseph J, Lang K, Niggemann B, Zaenker KS and Entschladen F: Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat. 80:63–70. 2003. View Article : Google Scholar : PubMed/NCBI
27	Lucin KM, Sanders VM and Popovich PG: Stress hormones collaborate to induce lymphocyte apoptosis after high level spinal cord injury. J Neurochem. 110:1409–1421. 2009. View Article : Google Scholar : PubMed/NCBI
28	Pérez Piñero C, Bruzzone A, Sarappa MG, Castillo LF and Lüthy IA: Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol. 166:721–736. 2012. View Article : Google Scholar
29	Zhang D, Ma QY, Hu HT and Zhang M: β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1. Cancer Biol Ther. 10:19–29. 2010. View Article : Google Scholar : PubMed/NCBI
30	Lang K and Bastian P: Neurotransmitter effects on tumor cells and leukocytes. Prog Exp Tumor Res. 39:99–121. 2007. View Article : Google Scholar : PubMed/NCBI
31	Carie AE and Sebti SM: A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 26:3777–3788. 2007. View Article : Google Scholar : PubMed/NCBI
32	Badino GR, Novelli A, Girardi C and Di Carlo F: Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res. 33:255–260. 1996. View Article : Google Scholar : PubMed/NCBI
33	Palm D, Lang K, Niggemann B, Drell TL IV, Masur K, Zaenker KS and Entschladen F: The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer. 118:2744–2749. 2006. View Article : Google Scholar